Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug consisting of thyroid hormone T4 (levothyroxine) and potassium iodide. Thyroid hormone T4 is a synthetic form of thyroxine, the primary hormone produced by the thyroid gland, which regulates metabolism, growth, and development. Potassium iodide provides stable (non-radioactive) iodine that can acutely block the release of endogenous thyroid hormones from the gland and rapidly decrease circulating levels in certain clinical situations. The combination may be used in specific scenarios such as managing severe hyperthyroidism or preparing patients for thyroid surgery when rapid normalization of thyroid function is required. The mechanism involves both direct hormonal replacement (T4) and inhibition of new hormone synthesis/release via high-dose iodine effect (potassium iodide). This combination is not standard therapy but may be considered in select cases under specialist supervision[1][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thyroid hormone T4 + potassium iodide.